Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa)

Next Previous
Trial Profile

QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 14 Nov 2022 Primary endpoint (Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) total score) has been met, according to Results published in the European Journal of Gastroenterology and Hepatology.
  • 14 Nov 2022 Results (n=93) assessing the impact of mesalazine treatment for mild to moderate ulcerative proctitis and proctosigmoiditis on patient quality of life, published in the European Journal of Gastroenterology and Hepatology.
  • 13 Oct 2020 Results (n=93) presented at the 28th United European Gastroenterology Week.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top